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Early diagnosis and more specific treatment may
improve PTL survival.
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Background and Objectives. To study the incidence,
clinical presentation, pathologic features and out-
come of post-transplant lymphomas (PTL) during
the past 20 years.
Design and Methods. We undertook a descriptive
study of all biopsy-proven cases of PTL diagnosed in
our hospital from 1979 through 1999. The average
annual incidence rate of PTL was analyzed at 5-year
intervals from 1979 to 1999. Risk ratios were esti-
mated by comparing the incidence of PTL among
transplanted patients with that of lymphoma
observed in the general population of the region.
Survival analysis was performed at the univariate
level using the Kaplan Meier technique and at the
multivariate level by Cox hazard models.
Results. Seventeen of 1,860 transplanted patients
developed a PTL (0.9%). The risk of PTL was calcu-
lated to be almost 8-fold higher than the risk of lym-
phoma in the general population. The risk was high-
est among those who had received a heart trans-
plant (RR=35.6). The mean time between trans-
plant and the diagnosis of PTL was 31 ± 29 months.
Of all PTL, 88% were of B-cell origin and 53% of the
cases tested were Epstein-Barr virus (EBV)-positive.
The median survival was 24 months. The majority of
patients with allograft involvement died within the
2 months following diagnosis (hazard ratio 5.3; 95%
CI 1.4-20.7).
Interpretation and Conclusions. Organ transplan-
tation is a major risk factor for the development of
lymphoma, a disease with a particularly bad prog-
nosis when it develops at the site of the allograft.
Lymphomas are one of the most frequenttumors occurring in organ transplant recipi-ents, comprising 20% of all neoplasms.1,2 They
are a serious complication and occur with an inci-
dence that ranges from 0.7% to 4.6%, depending
on the degree and duration of immunosuppression
used, the organ transplanted, and the age of the
transplant recipients.3-8 The induction of substan-
tial, prolonged immunosuppression seems to be
the main predisposing factor. Thus, a particularly
high incidence of post-transplant lymphomas (PTL)
was noted in patients receiving cyclosporin A, FK
506 and antibody OKT3 treatment.4,9
The majority of PTL are of B-cell origin, associ-
ated in most cases with Epstein-Barr virus (EBV)
infection;10,11 while, in contrast, T-cell PTL are
uncommon and mainly EBV-negative.12 Primary
EBV infection leads to latent infection of B-cells,
expressing part of the viral genome with episomal
EBV persistence. The control of these cells is
dependent on cytotoxic T-cells. Deliberate partial
suppression of T-cell function by immunosuppres-
sive drugs, in order to prevent graft rejection, is
believed to result in an uncontrolled EBV-driven
proliferation of B-cells. As proliferation continues,
B-cell clones with structural alterations enabling
autonomous growth escape immune control
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inducing a lymphoproliferative disease.13
The overall outcome of patients with PTL is poor
and about 50% of these patients die within a short
period after diagnosis.5,14 Prognostic factors are still
not defined and there is no uniform treatment
strategy.
Our aim was to describe the clinical presentation,
pathologic features, treatment and outcome of all
cases of PTL diagnosed in our hospital over the past
20 years. We also estimated the incidence of this
complication and the risk of lymphoma compared
to that observed in the general population.
Design and Methods
Patients
The analysis included all patients with PTL diag-
nosed from 1979 to 1999 at the Ciutat Sanitaria i
Universitaria de Bellvitge, a 1,000-bed teaching
institution in Barcelona, Spain that serves as a
referral transplant and cancer center for an area
with a population of more than 1 million adult
inhabitants.
Between January 1979 and December 1999 a
total of 1,860 solid organ transplants were per-
formed in our hospital: 1,173 renal, 547 hepatic,
and 140 cardiac transplants. Seventeen of the
transplant recipients developed a PTL. Information
regarding clinical, laboratory, and evolution data
were extracted from the medical records and from
files of the hospital’s lymphoma registry.
All diagnostic biopsy material was reviewed by
our pathologist. Morphologic and immunohisto-
chemical studies were performed in formalin-fixed,
paraffin-embedded tissue. PTL were classified
according to the REAL classification; those cases
seen prior to the date of publication of the REAL
classification were reclassified. Cases diagnosed as
polyclonal lymphoproliferative disease were
excluded from the study, in order to avoid a selec-
tion bias.
In situ hybridization for the detection of Epstein-
Barr encoded RNA (EBER) was performed on
involved paraffin-embedded tissues using com-
mercially available reagents (Dako, Denmark).
Definitions
Outcome was assessed by response to therapy,
remission duration, and survival. Complete remis-
sion was defined as no evidence of disease by stan-
dard laboratory, radiographic, or histopathologic
parameters; partial remission was defined as at
least a 50% decrease of the perpendicular diame-
ters of all measurable disease sites, without the
appearance of new lesions. Disease-free survival
was defined as the time from documentation of a
complete remission to relapse or death. Overall sur-
vival was defined as the time from diagnosis of the
lymphoproliferative disorder to death.
Statistical analysis
Results of the descriptive analysis are expressed
as means and standard deviations (SD) for contin-
uous data and number of cases with their propor-
tion for qualitative data.
The average annual incidence rate of PTL was
analyzed at 5-year intervals from 1979 to 1999,
inclusive. PTL incidence rates were calculated using
the number of new cases of PTL observed as the
numerator and the person-years at risk during the
study period as the denominator. Relative risks (RR)
were estimated by comparing the incidence of PTL
among transplanted patients with the incidence of
lymphoma in the general population of the region
(CIFC Vol 7).15 To control for age differences
between transplanted patients and the general
population, incidence rates were age-standardized.
Survival analysis was performed at the univari-
ate level by means of Kaplan-Meier techniques to
estimate overall survival. All variables were indi-
vidually evaluated in a hazard ratio model. Vari-
ables significantly related to survival were includ-
ed in a multivariate Cox proportional hazards
regression model. Results of the regression analy-
ses were expressed as a hazard ratio (HR), with its
95% confidence interval (CI). Values of p<0.05
were considered to be statistically significant.
Results
Incidence and relative risks
Between 1979 and 1999, 17 of 1,860 transplant-
ed patients (11 men and 6 women) developed a PTL.
This is an incidence of 0.9% for the whole 20-year
study period. The observed incidence of PTL among
the recipients of different types of transplant are
shown in Table 1. The annual incidence rate of PTL
was 43.5 per 105 transplants, which is an almost 8-
fold higher risk of lymphoma than in the general pop-
ulation. The risk of lymphoma was highest in those
patients receiving a heart transplant, with an inci-
dence rate of 357 per 105 heart transplants and a
35-fold higher risk than in the general population.
This risk increased up to 12 times when multiple
myeloma and Hodgkin’s disease were excluded from
the analysis. The incidence of PTL was stable through-
out the study period (p=0.79).
Clinical presentation and pathology
The main clinical and pathologic features of the
patient population with PTL are summarized in
Table 2. The mean age at time of diagnosis was
53±12 years (range: 27-73), and the mean time
between transplantation and diagnosis of PTL was
31±29 months  (range: 1-103). The median inter-
val between transplantation and PTL was shorter in
heart recipients (median 11 months; range=8-16
months) than in liver transplants (median 21
months; range 4.5-68 months) or renal transplants
(median 50 months; range 1-103 months). This
interval was also shorter after a second transplant
(n=3). PTL developed during the first year in 7
patients (41%).
As far as concerns histologic subtype, the 17 cas-
es of PTL comprised 4 polymorphic B-cell lym-
phomas, 3 large B-cell lymphomas, 2 mucosa asso-
ciated lymphomas (MALT), 2 Burkitt’s lymphomas,
2 plasmacytoma/multiple myeloma, 2 pleomorphic
B-cell lymphomas, 1 Hodgkin’s lymphoma, and 1
Sézary’s syndrome. Immunophenotypic studies
showed that 15 patients expressed markers of B-
cell lineage (88%), 1 Hodgkin’s disease and only 1
expressed T-cell lineage markers.
Staging and sites of involvement are also sum-
marized in Table 2. Of the 17 patients, 8 (47%) had
stage III or IV disease. Isolated extralymphoreticu-
lar disease was the most common presentation
(n=16), and the most frequently involved site was
the allograft (35%). No patient in our series pre-
sented central nervous system involvement.
EBV infection was evident in 7 of the 12 patients
tested (58%). In all of these cases, the PTL was of
B-cell origin.
Therapy and outcome
Therapeutic approach and response are summa-
rized in Table 3. After transplantation and before
the development of PTL, patients received immuno-
suppressive therapy for periods ranging from 1 to
103 months (median 16 months). All patients were
treated with prednisone and cyclosporin A and
some of them received additional immunosuppres-
sive drugs: azathioprine (4 patients), antithymocyte
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Table 1. Incidence of post-transplant lymphoma by 
transplanted organ.  
Transplanted Period No. of PTLD (%) AI RR (95%CI)*
organ transplants × 105
Kidney 1978-99 1173 8 (0.7) 32.5 5.8 (2.5-11.5)
Liver 1984-99 547 5 (0.9) 60.9 7.6 (2.5-17.8)
Heart 1991-99 140 4 (2.9) 357.1 35.7 (9.7-91.3)
Total 1978-99 1860 17 (0.9) 43.5 7.9 (4.6-12.7)
*Reference comparison with the regional rate of lymphomas in Tarragona, Spain.
CIFC Vol. VII.15 Abbreviations: AI: annual incidence; RR: relative risk.  
Table 2. Clinical features of patients with post-transplant lymphomas.
Patient Age (yrs)/Sex Organ transplanted Months between graft-PTLD Histology Tumor sites Stage LDH level EBV
1 61/M Liver 4.5 Plasmocytoma Liver IV-B 14.7 NA
2 57/M Kidney 44 MALT Stomach I-A NA —
3 48/M Kidney (×2) 103/23 Myeloma Maxillary bone II-A* 68 NA
4 65/F Liver 29 Diffuse large B-cell Parotid gland II-B 5.8 —
5 49/F Liver 68 Burkitt’s Diffuse IV-B NA +
6 45/M Kidney 4 Polymorphic B-cell Kidney IV-B NA +
7 73/F Kidney 14.5 Diffuse large B-cell Kidney IV-A 7.5 +
8 64/M Kidney (×2) 59/39 Hodgkin Liver IV-B 6.9 —
9 33/M Kidney 62 Polymorphic B-cell Lung I-A NA +
10 58/F Heart 16 Sézary’s syndrome Skin II-A 12.6 —
11 68/F Liver 21 MALT Orbit I-A 5 NA
12 51/M Liver (×2) 10.5/1 Diffuse large B-cell Liver IV-B NA —
13 60/M Heart 8 Pleomorphic B- cell Skin I-B 11.3 +
14 38/M Heart 8 Polymorphic B-cell Lung I-A 6.6 NA
15 59/M Heart 15 Polymorphic B-cell Intestinal IV-A 10.3 +
16 53/F Kidney 56.5 Burkitt’s Submaxillary gland II-A 8.1 +
17 27/M Kidney 1 Pleomorphic B-cell Kidney, liver IV-B NA NA
M= Male; F= Female; ×2= Double transplant; Staging according to Ann Arbor classification and *Durie and Salmon. LDH normal range: 0.1-7.5 µkat/L. NA= Not available.
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Table 3. Treatment and outcome of the patients with post-transplant lymphomas. 
Patient Immunosuppression (drug stopped) Antiviral Surgery Chemotherapy Radiotherapy Outcome
1 CSA + Azathioprine - - CHOP (1) Died progression 0.5 months
2 ↓ CSA - Gastrectomy - - CR +80 months
3 CSA - - CNOP (6) Local Died progression 23 months
4 CSA - - CHOP (6) Local Died progression 6 months
5 CSA + Azathioprine - - Leukemia-like (1) - Died progression 2 months
6 CSA + Cellcept - - - - Died progression 11 days
7 ↓ Cellcept - - CHOP (4) - PR + 25 months
8 ↓ CSA - - MOPP (2) - Died toxicity 2 months
9 CSA - Resection - - Died progression 12 months
10 CSA - - Chlorambucil + PUVA - CR +28 months Died myocardial infarction
11 No - - - Local CR + 8 months
12 ↓ CSA - - - - Died progression 1 month
13 ↓ CSA Acyclovir Resection - - CR + 50 months
14 ↓ Prednisone - Resection CHOP (6) - CR + 77 months
15 Azathioprine +↓ CSA - Resection CHOP (6) - CR + 75 months
16 ↓ CSA - - - Local CR + 52 months
17 CSA - - - - Died progression and sepsis 2 months
↓ = tapered; CR= complete remission; PR= partial remission; (number of cycles). Leukemia-like= High intensity, brief duration chemotherapy. McMaster ML. J Clin Oncol
1991.   
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globulin (ATG) (3 patients), azathioprine and ATG
(6 patients), cellcept (2 patients), and OKT3 (1
patient).
As shown in Table 3, in 16 patients immunosup-
pressive therapy was either modified or stopped
once the PTL had been diagnosed. In the remain-
ing case (patient #11) immunosuppression was not
modified and the patient received only orbital
radiotherapy. Fourteen patients received further
treatment including antiviral therapy with acy-
clovir, local radiotherapy, surgery and chemother-
apy. The most frequent chemotherapy scheme used
consisted of CHOP-based regimens (6 patients).
Overall survival is depicted in Figure 1. The medi-
an survival time was 24 months.
Five out of 8 patients who presented with local-
ized disease are alive and in complete remission,
without relapses through the study period and with
a median follow-up of 62 months (range 15 to 90
months). The majority of patients (five out of six)
who had allograft involvement died of progressive
disease within 2 months of diagnosis. Only one
patient (#7) is in partial remission, with a persist-
ing kidney allograft lesion and high LDH, but with-
out clinical manifestations.
Cox proportional hazards regression models were
used to evaluate the relationship between survival
and graft involvement (HR = 5.3; 95% CI 1.4 - 20.7)
(Figure 2). The other variables tested (age, sex, Ann
Arbor classification, EBV, LDH, transplanted organ
and time between transplant and PTL) did not
retain significant correlations.
Discussion
Solid organ transplantation has become a wide-
spread surgical intervention. The development of
subsequent PTL remains one of the most severe
complications in these patients. Although we have
a better understanding of the biology and patho-
genesis of these disorders, treatment is often inef-
fective and patients commonly die of this compli-
cation.
In this retrospective study on a cohort of 1,860
solid organ transplant recipients, 17 patients devel-
oped PTL (incidence 0.9%), which confirms the
reports of this complication available in the liter-
ature.1-8,10 The incidence of lymphoma differed sig-
nificantly in relation to the organ allografted: kid-
ney recipients had the lowest incidence rate (0.7%)
and heart recipients the highest (2.9%). The over-
all relative risk of PTL was almost 8-fold greater
than the risk of lymphoma in the general popula-
tion, and was especially high in heart transplant
recipients; this is most likely due to the more
aggressive immunosuppression therapy used in
these patients. We could not find differences in the
frequency of PTL along the study period, although
the immunosuppressive regimes varied.
The mean time between transplantation and the
diagnosis of PTL in our study group was 31 months.
However, the majority of PTL with graft involve-
ment were diagnosed within the first year after
transplantation. A higher incidence of lymphopro-
liferative diseases is reported in the literature to
occur in the early months following transplanta-
tion. The majority of cases were EBV-related poly-
clonal proliferations, which were not included in
our study.8,14 We also found that heart recipients
developed PTL earlier than kidney or liver trans-
plant recipients. This is thought to be a conse-
quence of the more intense immunosuppression
received in this period and of the type of organ
transplant.1-5
The histopathologic observations in our series
comply with the general concept that the great
majority of PTLs are of B-cell origin. In our study,
PTL was related to EBV infection in about 50% of
the cases tested, which is lower than that report-
ed by other authors.3,6,7,10,11 Moreover, we failed to
detect EBV in 30% of the B-cell PTLs. Underdetec-
tion of EBV cannot be ruled out in this retrospec-
tive series, although in situ hybridization for EBV
detection in our laboratory strongly correlated with
detection of this virus in other laboratories. Sever-
al studies consider EBV-negative PTL as a distinct
entity with late onset (>1 year after the transplant)
and a histologic and clinical presentation similar to
that of lymphomas that develop in immunocom-
petent subjects. This group of lymphomas might
be related to other infectious agents or genetic
changes.16,17
The outcome of our patients with PTL was poor.
In our study, PTL at the site of the graft was the
only statistically significant predictor of poor out-
come. As other authors have reported, up to 20%
of PTL can appear at the graft site.1,18,19 In the
majority of cases, PTL is an early complication after
transplantation that, at times, results in a mistak-
en diagnosis of rejection because of difficulty biop-
sies and similar symptoms. A number of hypothe-
ses have been formulated to explain this predispo-
sition to develop PTL in the graft: the large amount
of lymphoid tissue in these locations, stimulatory
factors released during the transplant procedure
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and differences in EBV serologies of donor and
recipient. The outcome of these patients is poor
because the PTL is difficult to treat, it progresses
rapidly and the graft is frequently lost. Other clin-
ical and laboratory data related to survival else-
where described14 did not show an association in
our study, probably because of the small number of
cases.
It is likely that early diagnosis and treatment may
improve the outcome of these patients. There are
groups working on monitoring EBV DNA load in
blood in order to identify those post-transplanted
patients at risk of developing a lymphoproliferative
disease.20 Early identification of patients at high
risk, together with a temporal reduction of immu-
nosuppression and a specific therapeutic approach
could reduce PTL-related morbidity and mortality
in these patients. Reduction of immunosuppres-
sion has been of great value in early-diagnosed
post-transplant lymphoproliferative diseases, espe-
cially polyclonal ones. The use of specific treat-
ments such as anti B-cell antibodies21,22 and EBV-
specific cytotoxic T-lymphocytes,23 are therapeutic
approaches with fewer side effects than those
observed using classic chemotherapy. It is likely
that the introduction of these new regimes will
improve survival. Further progress in the prevention
and treatment of this group of diseases will require
prospective clinical trials and standardized treat-
ment.
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Potential implications for clinical practice
Patients receiving a solid organ transplant have
almost an 8-fold higher risk of lymphoma than the
general population. The mortality caused by lym-
phoma localized to the site of the graft is up to five
times higher than the  mortality due to disease in
other locations.
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